Teva wins FDA nod for inhaled asthma medications

Teva Pharmaceuticals (NYSE:TEVA) said today that the FDA approved 2 inhaled asthma medications to be delivered using the company’s RespiClick breath-activated, multi-dose dry powder inhaler. The products, AirDuo RespiClick and ArmonAir RespiClick, are indicated for use in asthma patients as young as 12 years old.

The Jerusalem-based company’s AirDuo RespiClick is a fixed dose combination of a corticosteroid and a long-acting beta-adrenergic agonist, while the ArmonAir RespiClick is an inhaled corticosteroid.

Get the full story at our sister site, Drug Delivery Business News.

The post Teva wins FDA nod for inhaled asthma medications appeared first on MassDevice.

from MassDevice http://ift.tt/2jmuG0O